KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Eli Lilly (LLY) Tax Provisions (2016 - 2026)

Eli Lilly filings provide 18 years of Tax Provisions readings, the most recent being $1.5 billion for Q1 2026.

  • On a quarterly basis, Tax Provisions rose 108.61% to $1.5 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $5.8 billion, a 134.51% increase, with the full-year FY2025 number at $5.1 billion, up 143.59% from a year prior.
  • Tax Provisions hit $1.5 billion in Q1 2026 for Eli Lilly, down from $1.6 billion in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $1.6 billion in Q3 2025 to a low of $113.8 million in Q3 2022.
  • Median Tax Provisions over the past 5 years was $484.6 million (2023), compared with a mean of $618.3 million.
  • Biggest five-year swings in Tax Provisions: plummeted 32.06% in 2022 and later surged 325.83% in 2023.
  • Eli Lilly's Tax Provisions stood at $158.7 million in 2022, then surged by 100.95% to $318.9 million in 2023, then skyrocketed by 97.08% to $628.5 million in 2024, then soared by 159.11% to $1.6 billion in 2025, then dropped by 10.72% to $1.5 billion in 2026.
  • The last three reported values for Tax Provisions were $1.5 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.6 billion (Q3 2025) per Business Quant data.